このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Avacta Group マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Chris Coughlin

最高経営責任者

UK£53.0k

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	1.3yrs
取締役会の平均在任期間	2.6yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Chris Coughlin (54 yo)

less than a year

在職期間

UK£53,000

報酬

Dr. Christina M. Coughlin, also known as Chris, BS, MD, PH D., was Head of Research and Development of Avacta Group Plc from February 1, 2024 and serves as its Chief Executive Officer from May 01, 2024 and...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Christina Coughlin	CEO, Interim Chief Medical Officer and Director	less than a year	UK£53.00k	データなし
Tony Gardiner	CFO & Company Secretary	8.5yrs	UK£409.00k	0.0023% £ 5.8k
Emma Wright	Group In-House Counsel	no data	データなし	データなし
Michael Vinegrad	Group Communications Director	3.5yrs	データなし	データなし
R. Slater	Chief Operating Officer of Diagnostics	7.9yrs	UK£69.00k	データなし
Matt Johnson	Chief Scientific Officer of Diagnostics	3.5yrs	データなし	データなし
David Wilson	Chief Commercial Officer of Diagnostics	1.5yrs	データなし	データなし
Karen Harrison	Chief Operating Officer of Therapeutics Division	1.3yrs	データなし	データなし
Anne McGurk	Joint Managing Director of Launch Diagnostics	1.3yrs	データなし	データなし
Ian Jones	Joint Managing Director of Launch Diagnostics	1.3yrs	データなし	データなし
Simon Bennett	Chief Business Officer of Therapeutics	less than a year	データなし	データなし
Sebastien Goenen	Chief Operating Officer of Coris BioConcept	1.3yrs	データなし	データなし

1.3yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: AVCT.Fの経営陣は経験豊富とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Christina Coughlin	CEO, Interim Chief Medical Officer and Director	2.3yrs	UK£53.00k	データなし
Trevor Nicholls	Independent Non-Executive Director	10.9yrs	UK£47.00k	0.030% £ 75.4k
Shaun Chilton	Non-Executive Independent Chairman	1.1yrs	UK£26.00k	データなし
Mark A. Goldberg	Independent Non-Executive Director	2.9yrs	UK£53.00k	データなし
Paul Fry	Independent Non-Executive Director	4.4yrs	UK£47.00k	データなし
James Spicer	Member of Scientific Advisory Board	2.8yrs	データなし	データなし
Krishna Komanduri	Member of Scientific Advisory Board	2.8yrs	データなし	データなし
Stephane Champiat	Member of Scientific Advisory Board	2.8yrs	データなし	データなし
Alan Ho	Member of Scientific Advisory Board	less than a year	データなし	データなし
William Tap	Chairman of Scientific Advisory Board	less than a year	データなし	データなし
Andrea Napolitano	Member of Scientific Advisory Board	less than a year	データなし	データなし
Lee Cranmer	Member of Scientific Advisory Board	less than a year	データなし	データなし

2.6yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: AVCT.Fの取締役会は経験豊富ではない ( 2.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Avacta Group マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Avacta Group plc Announces Board Changes

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Recent updates

Avacta Group plc Announces Board Changes

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

Avacta Group Plc Announces Pre-Clinical Development Milestone in LG Chem Life Sciences Partnership

Avacta Group plc Provides Update on AffiDX Lateral Flow Test

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

MHRA Confirms Registration of Avacta’s Affidx® SARS-CoV-2 Antigen Lateral Flow Test

Avacta Group plc Provides an Update on Lateral Flow Test Regulatory Submissions

Avacta Signs Diagnostic Licensing Deal with Biokit

Avacta Group plc Announces its AffiDX SARS-CoV-2 Rapid Antigen Lateral Flow Test Detects the Dominant New Variants of the Coronavirus

Avacta Announces Phase 1 Clinical Trial Authorisation (CTA) for AVA6000 Approved by MHRA

Avacta Group plc Announces Results of Initial Evaluation of Sars-Cov-2 Lateral Flow Antigen Test with Clinical Samples

Avacta Group plc Enters into Commercial Partnership with Mologic Ltd

Avacta Announces Collaboration Agreement with Bruker

Avacta Group plc Announces License Agreement with Point Biopharma Inc

Avacta Submits Clinical Trial Application for Ava6000 Pro-Doxorubixin

Gamma Biosciences Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer® Reagent Technology

Avacta Group plc Announces Significant Progress in Development of a Highly Scalable Manufacturing Process for Lateral Flow SARS-CoV-2 Antigen Test

Avacta Group Plc Launches SARS-CoV-2 BAMS Research Test

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14